11,085 Shares in Merck & Co., Inc. (MRK) Purchased by Farmers & Merchants Trust Co of Chambersburg PA

Share on StockTwits

Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 11,085 shares of the company’s stock, valued at approximately $673,000.

Several other institutional investors have also recently modified their holdings of MRK. Franklin Resources Inc. lifted its stake in Merck & Co., Inc. by 13.6% in the 1st quarter. Franklin Resources Inc. now owns 49,101,614 shares of the company’s stock valued at $2,674,552,000 after purchasing an additional 5,880,457 shares during the last quarter. Macquarie Group Ltd. increased its position in Merck & Co., Inc. by 5.4% in the 4th quarter. Macquarie Group Ltd. now owns 11,698,584 shares of the company’s stock valued at $658,298,000 after acquiring an additional 597,089 shares during the period. Schwab Charles Investment Management Inc. increased its position in Merck & Co., Inc. by 2.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 10,609,836 shares of the company’s stock valued at $577,918,000 after acquiring an additional 238,896 shares during the period. American Century Companies Inc. increased its position in Merck & Co., Inc. by 13.3% in the 1st quarter. American Century Companies Inc. now owns 9,567,645 shares of the company’s stock valued at $521,150,000 after acquiring an additional 1,125,931 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in Merck & Co., Inc. by 5.8% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,742,471 shares of the company’s stock valued at $530,668,000 after acquiring an additional 479,302 shares during the period. 72.20% of the stock is owned by institutional investors.

Merck & Co., Inc. stock opened at $69.67 on Friday. Merck & Co., Inc. has a 1-year low of $52.83 and a 1-year high of $70.25. The firm has a market capitalization of $185.01 billion, a price-to-earnings ratio of 17.51, a price-to-earnings-growth ratio of 2.37 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.03. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The firm had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. During the same period last year, the firm earned $1.01 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. equities research analysts predict that Merck & Co., Inc. will post 4.26 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be given a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date of this dividend is Friday, September 14th. Merck & Co., Inc.’s payout ratio is currently 48.24%.

In related news, Chairman Kenneth C. Frazier sold 228,091 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the transaction, the chairman now directly owns 938,788 shares of the company’s stock, valued at $61,021,220. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sanat Chattopadhyay sold 29,208 shares of the firm’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the transaction, the insider now directly owns 70,675 shares in the company, valued at $4,608,010. The disclosure for this sale can be found here. Insiders have sold 396,393 shares of company stock worth $25,235,061 over the last three months. 0.32% of the stock is owned by insiders.

Several equities analysts have issued reports on the stock. Barclays upped their price target on shares of Merck & Co., Inc. from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday. Zacks Investment Research cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, June 18th. SunTrust Banks reiterated a “buy” rating and set a $77.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. TheStreet upgraded shares of Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research report on Friday, June 8th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $70.00 price objective on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $67.93.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Story: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply